Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 16.77 USD -5.52% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Arcus Biosciences Inc?
Write Note

Intrinsic Value

RCUS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RCUS stock under the Base Case scenario is 14.85 USD. Compared to the current market price of 16.77 USD, Arcus Biosciences Inc is Overvalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RCUS Intrinsic Value
14.85 USD
Overvaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arcus Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RCUS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RCUS?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Arcus Biosciences Inc

Provide an overview of the primary business activities
of Arcus Biosciences Inc.

What unique competitive advantages
does Arcus Biosciences Inc hold over its rivals?

What risks and challenges
does Arcus Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Arcus Biosciences Inc recently?

Summarize the latest earnings call
of Arcus Biosciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Arcus Biosciences Inc.

Provide P/S
for Arcus Biosciences Inc.

Provide P/E
for Arcus Biosciences Inc.

Provide P/OCF
for Arcus Biosciences Inc.

Provide P/FCFE
for Arcus Biosciences Inc.

Provide P/B
for Arcus Biosciences Inc.

Provide EV/S
for Arcus Biosciences Inc.

Provide EV/GP
for Arcus Biosciences Inc.

Provide EV/EBITDA
for Arcus Biosciences Inc.

Provide EV/EBIT
for Arcus Biosciences Inc.

Provide EV/OCF
for Arcus Biosciences Inc.

Provide EV/FCFF
for Arcus Biosciences Inc.

Provide EV/IC
for Arcus Biosciences Inc.

Show me price targets
for Arcus Biosciences Inc made by professional analysts.

What are the Revenue projections
for Arcus Biosciences Inc?

How accurate were the past Revenue estimates
for Arcus Biosciences Inc?

What are the Net Income projections
for Arcus Biosciences Inc?

How accurate were the past Net Income estimates
for Arcus Biosciences Inc?

What are the EPS projections
for Arcus Biosciences Inc?

How accurate were the past EPS estimates
for Arcus Biosciences Inc?

What are the EBIT projections
for Arcus Biosciences Inc?

How accurate were the past EBIT estimates
for Arcus Biosciences Inc?

Compare the revenue forecasts
for Arcus Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Arcus Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Arcus Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Arcus Biosciences Inc compared to its peers.

Compare the P/E ratios
of Arcus Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Arcus Biosciences Inc with its peers.

Analyze the financial leverage
of Arcus Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Arcus Biosciences Inc.

Provide ROE
for Arcus Biosciences Inc.

Provide ROA
for Arcus Biosciences Inc.

Provide ROIC
for Arcus Biosciences Inc.

Provide ROCE
for Arcus Biosciences Inc.

Provide Gross Margin
for Arcus Biosciences Inc.

Provide Operating Margin
for Arcus Biosciences Inc.

Provide Net Margin
for Arcus Biosciences Inc.

Provide FCF Margin
for Arcus Biosciences Inc.

Show all solvency ratios
for Arcus Biosciences Inc.

Provide D/E Ratio
for Arcus Biosciences Inc.

Provide D/A Ratio
for Arcus Biosciences Inc.

Provide Interest Coverage Ratio
for Arcus Biosciences Inc.

Provide Altman Z-Score Ratio
for Arcus Biosciences Inc.

Provide Quick Ratio
for Arcus Biosciences Inc.

Provide Current Ratio
for Arcus Biosciences Inc.

Provide Cash Ratio
for Arcus Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Arcus Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Arcus Biosciences Inc?

What is the current Free Cash Flow
of Arcus Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Arcus Biosciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Arcus Biosciences Inc

Current Assets 1.1B
Cash & Short-Term Investments 1.1B
Receivables 21m
Other Current Assets 17m
Non-Current Assets 125m
Long-Term Investments 2m
PP&E 48m
Other Non-Current Assets 75m
Current Liabilities 215m
Accounts Payable 13m
Accrued Liabilities 97m
Other Current Liabilities 105m
Non-Current Liabilities 472m
Long-Term Debt 47m
Other Non-Current Liabilities 425m
Efficiency

Earnings Waterfall
Arcus Biosciences Inc

Revenue
263m USD
Operating Expenses
-561m USD
Operating Income
-298m USD
Other Expenses
28m USD
Net Income
-270m USD

Free Cash Flow Analysis
Arcus Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RCUS Profitability Score
Profitability Due Diligence

Arcus Biosciences Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Exceptional Revenue Growth Forecast
30/100
Profitability
Score

Arcus Biosciences Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

RCUS Solvency Score
Solvency Due Diligence

Arcus Biosciences Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
62/100
Solvency
Score

Arcus Biosciences Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RCUS Price Targets Summary
Arcus Biosciences Inc

Wall Street analysts forecast RCUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RCUS is 32.92 USD with a low forecast of 20.2 USD and a high forecast of 48.3 USD.

Lowest
Price Target
20.2 USD
20% Upside
Average
Price Target
32.92 USD
96% Upside
Highest
Price Target
48.3 USD
188% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RCUS?

Click here to dive deeper.

Dividends

Arcus Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RCUS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RCUS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

RCUS News

Profile

Arcus Biosciences Inc Logo
Arcus Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.5B USD

Dividend Yield

0%

Description

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 366 full-time employees. The company went IPO on 2018-03-15. The firm's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The firm's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.

Contact

CALIFORNIA
Hayward
3928 Point Eden Way
+15106946200.0
arcusbio.com

IPO

2018-03-15

Employees

366

Officers

Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
Co- Founder & President
Dr. Juan Carlos Jaen Ph.D.
Principal Financial Officer & CFO
Mr. Robert C. Goeltz II
Chief Operating Officer
Ms. Jennifer A. Jarrett M.B.A.
Chief Medical Officer
Dr. Dimitry S.A. Nuyten M.D., Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. K. Christopher Garcia Ph.D.
Show More
VP of Finance & Principal Accounting Officer
Mr. Alexander Azoy
Chief Scientific Officer
Dr. Jonathan Yingling Ph.D.
General Counsel & Corporate Secretary
Ms. Carolyn C. Tang J.D.
Vice President of Corporate Communications
Holli Kolkey
Show Less

See Also

Discover More
What is the Intrinsic Value of one RCUS stock?

The intrinsic value of one RCUS stock under the Base Case scenario is 14.85 USD.

Is RCUS stock undervalued or overvalued?

Compared to the current market price of 16.77 USD, Arcus Biosciences Inc is Overvalued by 11%.

Back to Top